Kalaris Therapeutics (NASDAQ:KLRS) Raised to Hold at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

KLRS has been the subject of a number of other research reports. Raymond James Financial initiated coverage on Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. Citizens Jmp initiated coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kalaris Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Kalaris Therapeutics Stock Performance

NASDAQ:KLRS opened at $9.10 on Friday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The firm has a 50-day moving average price of $6.00 and a two-hundred day moving average price of $4.34. The firm has a market cap of $170.17 million, a price-to-earnings ratio of -2.41 and a beta of -0.04.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Kalaris Therapeutics during the second quarter worth about $65,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $231,000. Belpointe Asset Management LLC purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $231,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics in the 3rd quarter worth approximately $58,000. Finally, Bridgeway Capital Management LLC purchased a new position in Kalaris Therapeutics in the 3rd quarter valued at approximately $130,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.